Study of HB0017 for people with plaque psoriasis
Part of Skin clinical trials.
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have had plaque psoriasis for at least 6 months
- Your psoriasis covers at least 10% of your body surface area and is moderate to severe
- You have not previously taken a drug that targets IL-17 or its receptor
- You have not used certain biologic treatments within specific time frames before joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental oral tablet (CMS-D001) to see if it can safely and effectively reduce the severity of moderate to severe plaque psoriasis. It may be an easier treatment option compared to injections or light therapy.
This trial tests an experimental drug called ICP-488 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve symptoms and is safe, and may be an option if you need stronger treatment than creams or light therapy.
This study tests an investigational medicine (HS-20118) for people with moderate-to-severe plaque psoriasis. The goal is to see if the drug can safely and effectively reduce psoriasis symptoms and improve quality of life.
This study tests a new medicine (HS-20137) for moderate-to-severe plaque psoriasis, a condition causing thick, scaly patches on the skin. It aims to see if this medicine can safely reduce the severity of psoriasis and improve quality of life.
This trial tests a new medication (HS-10374) taken by mouth to see if it is safe and effective for people with moderate to severe plaque psoriasis. It might help reduce the redness, scaling, and thickness of psoriasis plaques.
This trial tests a new study drug called HSK44459 for people with moderate to severe plaque psoriasis. The hope is that the drug can reduce psoriasis symptoms and improve quality of life. Participation involves receiving the study drug and being monitored for safety and effectiveness.
Hear when a new Psoriasis (PsO) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.